대웅
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| 매출액 | 1,511,373,580,813 | 1,697,338,482,580 | 1,813,841,462,124 | 1,936,916,852,599 | 2,068,370,455,244 | KRW |
| 영업이익 | 182,627,158,402 | 207,334,242,877 | 195,606,282,852 | 281,913,080,239 | 261,793,894,978 | KRW |
| 당기순이익 | 78,807,737,167 | 102,565,588,552 | 152,665,121,743 | 57,885,500,089 | 175,062,902,534 | KRW |
| 자본총계 | 730,557,648,345 | 828,828,700,588 | 934,796,127,926 | 996,506,946,105 | 1,176,637,791,557 | KRW |
| 부채총계 | 776,674,438,964 | 879,409,305,644 | 922,478,396,685 | 1,218,198,152,023 | 1,464,831,571,447 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 106.31 | 106.10 | 98.68 | 122.25 | 124.49 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 15,540
- 80%
- 14,999.79 ~ 16,076.68
- 90%
- 14,838.87 ~ 16,317
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-09-04Filing title as filed타인에대한채무보증결정(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-09-02Filing title as filed소송등의제기ㆍ신청(일정금액이상의청구)(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-07-10Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 국내 3상 임상시험계획(IND) 승인(미란성 위식도역류질환 치료 후 유지요법)) original ↗Source: dart_disclosure
- 2026-06-30Filing title as filed[기재정정]신규시설투자등(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-06-26Filing title as filed단일판매ㆍ공급계약체결(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-06-23Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 3상 임상시험계획(IND) 승인(위궤양의 치료 요법)) original ↗Source: dart_disclosure
- 2026-06-01Filing title as filed기업지배구조보고서공시 original ↗Source: dart_disclosure
- 2026-05-26Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (엔블로젬(Envlozem)의 국내 품목허가 신청) original ↗Source: dart_disclosure
- 2026-05-26Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (엔블로정(Envlo) 0.3mg 멕시코 품목허가 승인) original ↗Source: dart_disclosure
- 2026-05-21Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (비만치료용 세마글루타이드(4주 장기지속형 주사제) 기술도입 계약 체결) original ↗Source: dart_disclosure
- 2026-05-20Filing title as filed[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계) original ↗Source: dart_disclosure
- 2026-05-15Filing title as filed분기보고서 (2026.03) original ↗Source: dart_disclosure
- 2026-05-12Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (INV008(15PGDH 저해제) 기술도입 계약 체결) original ↗Source: dart_disclosure
- 2026-05-07Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계) original ↗Source: dart_disclosure
- 2026-04-30Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 국내 품목허가 승인(헬리코박터파일로리 제균을 위한 항생제 병용요법)) original ↗Source: dart_disclosure
- 2026-04-10Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-03-26Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-03-26Filing title as filed정기주주총회결과 original ↗Source: dart_disclosure
- 2026-03-23Filing title as filed감사보고서제출(자회사의 주요경영사항) original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…